Expert Interview
Looking at the current use of MRD testing in oncology and the recent ASCO data presented from Natera on their Signatera MRD studies for solid tumors
Ticker(s): NTRA, GH, ADPTInstitution: Rocky Mountain Cancer Centers
- Breast Oncologist at Rocky Mountain Cancer Centers
- Manages 50+ patients with breast cancer
- Principal investigator for numerous breast cancer clinical trials and has presented at national cancer conferences including ASCO and SABCS
Roughly how many patients do you see per month for blood cancers (Leukemia, Lymphoma, Myelodysplastic Syndromes (MDS), Myeloproliferative Disorder (MPD), Multiple Myeloma)?
Added By: ben_adminHave you ordered any of the following Measurable residual disease (MRD) tests: A) Signatera from Natera Oncology, B) Reveal from Guardant Health, C) ClonoSEQ from Adaptive Biotech?
Added By: ben_adminWhat are the differences between the current MRD tests on the market?
Added By: ben_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
